Fresh Tracks Therapeutics, Inc.

NASDAQ
FRTX
Terfi
Altı ay boyunca karlılık: +0.5376%
Temettü getirisi: 0%
Sektör: Healthcare

0.935 $

-0.005 $ -0.5319%
0.65 $
0.94 $

Min./max. bir yıl boyunca

Promosyon programı Fresh Tracks Therapeutics, Inc.

Genişletilmiş Program Basit Program
Financial Markets by TradingView
Karşılaştırma ekle
Parça Ekle
Portföye ekle
Fiyat Bildirimi Ekle

Ana parametreler

Halka arz süresi
2022-09-08
ISIN
US10802T2042
Para birimi
usd
Raporun para birimi
usd
Sanayi
Biotechnology
Sektör
Health Care
Web sitesi
Sistem
Tüm parametreler

Seviye

Hafife alma
İsim Anlam Seviye
P/S 0.5982 10
P/BV 0.4823 10
P/E 0 0
Yeterlik
İsim Anlam Seviye
ROA -49.15 0
ROE -57.34 0
ROIC 0 0
Temettü
İsim Anlam Seviye
Temettü getirisi 0 0
DSI 0 0
Temettülerin ortalama büyümesi 0 0
Görev
İsim Anlam Seviye
Debt/EBITDA 0 10
Debt/Ratio 0 10
Debt/Equity 0.1668 10
Büyüme darbesi
İsim Anlam Seviye
Gelir, milyar, % 1.34 1
Ebitda, % -76.95 0
EPS, % -99.75 0
Devamını oku

Fiyat

Fiyat Min. Maksimum. Değiştirmek Sektördeki değişiklikler Dizindeki değişiklikler
Dün 0.94 $ 0 $ 0 $ -0.5319 % 0 % 0 %
Hafta 0.94 $ 0 $ 0 $ -0.5319 % 0 % 0 %
Ay 0.94 $ 0 $ 0 $ -0.5319 % 0 % 0 %
3 ay 0.94 $ 0.935 $ 0.94 $ -0.5319 % 0 % 0 %
Altı ay 0.93 $ 0.91 $ 0.94 $ +0.5376 % 0 % 0 %
Yıl 0.72 $ 0.65 $ 0.94 $ +29.86 % 0 % 0 %
3 yıl 0.49 $ 0.49 $ 2.5 $ +191.84 % 0 % 0 %
5 yıl 0.49 $ 0.49 $ 2.5 $ +191.84 % 0 % 0 %
10 yıl 0.49 $ 0.49 $ 2.5 $ +191.84 % 0 % 0 %
Sene başından beri 0.71 $ 0.65 $ 0.94 $ +31.69 % 0 % 0 %

Temel Sahipler

Benzer Şirketler

P/E & P/BVEV/Ebitda & Debt/Ebitda


Şirketin yönetimi

Amir İş unvanı Ödeme Doğum yılı
Mr. Albert Nicholas Marchio II CEO, CFO, Secretary & Chairman 251.83k 1952 (73 yıl)
Aron Aizenstat M.B.A., P.M.P. Vice President of Corporate Development & Operations N/A
Ms. Sue Fattor Head of Human Resource N/A
Dr. James S. McElvain Ph.D. Interim Head of CMC Development N/A
Mr. Aaron Fox-Collis CPA VP of Finance & Chief Accounting Officer N/A

Şirket hakkında bilgi

Adres: United States, Boulder. CO, 5777 Central Avenue - Google kartlarında açın, Açık yandex kartları
Web sitesi: https://www.frtx.com

Şirket hakkında Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.